Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure

• Published in: Mediterranean journal of hematology and infectious diseases Vol. 5; no. 1; p. e2013037
• Main Authors: Tosi, Patrizia, Gamberi, Barbara, Castagnari, Barbara, Molinari, Anna Lia, Savini, Paolo, Ceccolini, Michela, Tani, Monica, Merli, Anna, Imola, Manuela, Mianulli, Anna Maria, Cellini, Claudia, Tomassetti, Simona, Merli, Francesco, Fattori, Pierpaolo, Zaccaria, Alfonso
• Format: Journal Article
• Language: English
• Published: Italy Università Cattolica del Sacro Cuore 01-01-2013; Mattioli1885
• Subjects: Myeloma, Renal failure, Lenalidomide; Original
• ISSN: 2035-3006; 2035-3006
• DOI: 10.4084/MJHID.2013.037

Salvage therapy of elderly patients with advanced, relapsed and refractory multiple myeloma (MM) is often limited by poor marrow reserve and multi-organ impairment. In particular, renal failure occurs in up to 50% of such patients, and this can potentially limit the therapeutic options. Both thalidomide and bortezomib have proven effective in these patients, with an acceptable toxicity, while, in clinical practice, lenalidomide is generally not considered a first-choice drug for MM patients with renal failure as early reports showed an increased hematological toxicity unless appropriate dose reduction is applied. Aim of this study was a retrospective evaluation of the efficacy of the combination Lenalidomide + Dexamethasone in a population of elderly MM patients treated in 5 Italian Centers. The study included 20 consecutive MM patients (9 M, 11 F, median age 76.5 years) with relapsed (N= 6) or refractory (N=13) MM and moderate to severe renal failure, defined as creatinine clearance (Cr Cl) < 50ml/min. Four patients were undergoing hemodyalisis at study entry. 85 % of the patients had been previously treated with bortezomib-containing regimens. Lenalidomide dose was adjusted according to renal function and patients clinical conditions Median treatment duration was 16 months (1-22), therapy was interrupted after 1 21-day cycle in 2 patients. Grade III-IV neutropenia was observed in 7 patients (35%); grade III-IV non hematological toxicity was recorded in 3 cases (28%). A > partial response was observed in 8 patients (40%), 1 of whom obtained a VGPR; 4 additional patients achieved a minor response. Median response duration was 16 months (range 2-19+ months). A complete and partial renal response was obtained in 4 and 3 patients, respectively, all of them were responsive to Lenalidomide-dexamethasone According to our data, LEN+DEX has shown efficacy and acceptable toxicity in this population of elderly patients with advanced MM and renal failure.